 Antineoplastic Agents
"Antineoplastic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000970
|
| MeSH Number(s) |
D27.505.954.248
|
| Concept/Terms |
Antineoplastic Agents- Antineoplastic Agents
- Agents, Antineoplastic
- Antitumor Drugs
- Drugs, Antitumor
- Antitumor Agents
- Agents, Antitumor
- Antineoplastic Drugs
- Drugs, Antineoplastic
- Antineoplastics
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents".
This graph shows the total number of publications written about "Antineoplastic Agents" by people in this website by year, and whether "Antineoplastic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 6 | 6 | 12 | | 1981 | 5 | 3 | 8 | | 1982 | 9 | 4 | 13 | | 1983 | 6 | 1 | 7 | | 1984 | 3 | 0 | 3 | | 1985 | 2 | 1 | 3 | | 1986 | 4 | 2 | 6 | | 1987 | 3 | 2 | 5 | | 1988 | 6 | 0 | 6 | | 1989 | 6 | 2 | 8 | | 1990 | 2 | 3 | 5 | | 1991 | 3 | 1 | 4 | | 1992 | 6 | 5 | 11 | | 1993 | 7 | 1 | 8 | | 1994 | 12 | 2 | 14 | | 1995 | 6 | 2 | 8 | | 1996 | 13 | 3 | 16 | | 1997 | 8 | 1 | 9 | | 1998 | 24 | 7 | 31 | | 1999 | 9 | 9 | 18 | | 2000 | 19 | 9 | 28 | | 2001 | 25 | 7 | 32 | | 2002 | 41 | 14 | 55 | | 2003 | 34 | 12 | 46 | | 2004 | 42 | 14 | 56 | | 2005 | 34 | 20 | 54 | | 2006 | 43 | 20 | 63 | | 2007 | 51 | 19 | 70 | | 2008 | 37 | 19 | 56 | | 2009 | 45 | 26 | 71 | | 2010 | 60 | 28 | 88 | | 2011 | 64 | 20 | 84 | | 2012 | 57 | 26 | 83 | | 2013 | 56 | 25 | 81 | | 2014 | 74 | 25 | 99 | | 2015 | 78 | 36 | 114 | | 2016 | 63 | 29 | 92 | | 2017 | 46 | 24 | 70 | | 2018 | 42 | 26 | 68 | | 2019 | 47 | 23 | 70 | | 2020 | 31 | 16 | 47 | | 2021 | 44 | 12 | 56 | | 2022 | 7 | 2 | 9 |
To return to the timeline, click here.
Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Boni V, Fidler MJ, Arkenau HT, Spira A, Meric-Bernstam F, Uboha N, Sanborn RE, Sweis RF, LoRusso P, Nagasaka M, Garcia-Corbacho J, Jalal S, Harding JJ, Kim SK, Miedema IHC, Vugts DJ, Huisman MC, Zwezerijnen GJC, van Dongen GAMS, Menke van der Houven van Oordt CW, Wang S, Dang T, Zein IA, Vasiljeva O, Lyman SK, Paton V, Hannah A, Liu JF. Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clin Cancer Res. 2022 May 13; 28(10):2020-2029.
-
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, Kerr K, Wang C, Ciuleanu TE, Saylors GB, Tanaka F, Ito H, Chen KN, Liberman M, Vokes EE, Taube JM, Dorange C, Cai J, Fiore J, Jarkowski A, Balli D, Sausen M, Pandya D, Calvet CY, Girard N. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022 05 26; 386(21):1973-1985.
-
Le X, Sakai H, Felip E, Veillon R, Garassino MC, Raskin J, Cortot AB, Viteri S, Mazieres J, Smit EF, Thomas M, Iams WT, Cho BC, Kim HR, Yang JC, Chen YM, Patel JD, Bestvina CM, Park K, Griesinger F, Johnson M, Gottfried M, Britschgi C, Heymach J, Sikoglu E, Berghoff K, Schumacher KM, Bruns R, Otto G, Paik PK. Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clin Cancer Res. 2022 03 15; 28(6):1117-1126.
-
Fan W, Wei Q, Xiang J, Tang Y, Zhou Q, Geng Y, Liu Y, Sun R, Xu L, Wang G, Piao Y, Shao S, Zhou Z, Tang J, Xie T, Li Z, Shen Y. Mucus Penetrating and Cell-Binding Polyzwitterionic Micelles as Potent Oral Nanomedicine for Cancer Drug Delivery. Adv Mater. 2022 Apr; 34(16):e2109189.
-
Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678.
-
Romani P, Nirchio N, Arboit M, Barbieri V, Tosi A, Michielin F, Shibuya S, Benoist T, Wu D, Hindmarch CCT, Giomo M, Urciuolo A, Giamogante F, Roveri A, Chakravarty P, Montagner M, Calì T, Elvassore N, Archer SL, De Coppi P, Rosato A, Martello G, Dupont S. Mitochondrial fission links ECM mechanotransduction to metabolic redox homeostasis and metastatic chemotherapy resistance. Nat Cell Biol. 2022 02; 24(2):168-180.
-
Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH. Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis. Support Care Cancer. 2022 Feb; 30(2):1015-1018.
-
Hammel JH, Zatorski JM, Cook SR, Pompano RR, Munson JM. Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics. Adv Drug Deliv Rev. 2022 03; 182:114111.
-
Mascia F, Mazo I, Alterovitz WL, Karagiannis K, Wu WW, Shen RF, Beaver JA, Rao VA. In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Vernieri C, Fucà G, Ligorio F, Huber V, Vingiani A, Iannelli F, Raimondi A, Rinchai D, Frigè G, Belfiore A, Lalli L, Chiodoni C, Cancila V, Zanardi F, Ajazi A, Cortellino S, Vallacchi V, Squarcina P, Cova A, Pesce S, Frati P, Mall R, Corsetto PA, Rizzo AM, Ferraris C, Folli S, Garassino MC, Capri G, Bianchi G, Colombo MP, Minucci S, Foiani M, Longo VD, Apolone G, Torri V, Pruneri G, Bedognetti D, Rivoltini L, de Braud F. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 01; 12(1):90-107.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|